STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
Stat News • 10/22/2026 – 10/23/2026
Summary
The U.S. is set to propose a rule that will impose additional scrutiny on outbound licensing deals with Chinese biotech companies. Additionally, Belgium is refusing coverage for the drug Mounjaro.
Advertisement
Lindy Score Breakdown (V4.2)
10h
Age
1
Sources
from cluster
8
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier89% (0.5^8/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
Stat News • 2 days ago
STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
Stat News • Today
STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
Stat News • Today
STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
Stat News • Today
STAT+: Crackdowns loom, from China to New York
Stat News • Today
STAT+: What to expect from the Moderna-Merck cancer vaccine data reveal
Stat News • Today
STAT+: Nutrition experts press White House to release ultra-processed food definition
Stat News • Today
STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
Stat News • 1 day ago
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
Stat News • Today
